SOBI acquires rights outside China to SEL 212 a proposed treatment for gout from Selecta Biosciences
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Selecta Biosciences, Inc. announced that the companies have entered into a strategic licensing agreement for the product candidate SEL 212. SEL… read more.